Estrella Immunopharma Inc (ESLA)

$0.66 -0.01 (-1.99%)
Market Cap 28.69M
Revenue (ttm) 0.00
Net Income (ttm) -13.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,900
Avg Vol 35,716
Day's Range N/A - N/A
Shares Out 43.50M
Stochastic %K 47%
Beta 0.88
Analysts Strong Buy
Price Target $12.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
Stay_Greens
Stay_Greens Sep. 7 at 11:48 PM
$ONMD $ESLA $PAAI $ONMD $SLXN $BYRN this week
1 · Reply
stinstewart
stinstewart Sep. 4 at 6:36 PM
$ESLA a lot of insider activity in August. Go to their website under investors and look at filings. FYI and For whatever that is worth. Low cash isn't good but this company has high insider stock ownership and i thought the last raise was at market price when stock was trading in the 1.40 area.
0 · Reply
ZacksSCR
ZacksSCR Aug. 26 at 4:44 PM
$ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial https://buff.ly/jII5QIv
0 · Reply
rolandpuski
rolandpuski Jul. 17 at 3:43 PM
$ESLA volume spike... 0,94
0 · Reply
BonjerminFranklin
BonjerminFranklin Jul. 16 at 6:33 PM
$ESLA wtf happen here!! Lowest of lows. Goes to .50 cents will take a casino spin for the double up.
0 · Reply
ZacksSCR
ZacksSCR Jul. 14 at 2:23 PM
$ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma? https://buff.ly/23P2R3Z
0 · Reply
focafoca99
focafoca99 Jun. 30 at 9:48 PM
$ESLA ratified the appointment of Macias Gini & O'Connell LLP as its independent accounting firm at the annual meeting.
0 · Reply
topstockalerts
topstockalerts Jun. 23 at 1:15 PM
Pre Market Top Gainers PT2 $MGN $GITS $VTAK $BLZE $ESLA
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 11 at 1:55 AM
$ESLA
0 · Reply
MTRADe_01
MTRADe_01 Jun. 5 at 2:04 PM
$ESLA Not a squeeze play. But… ✅ Float: ~14.1M ✅ Trading near 52-week lows ✅ Volume running above average ✅ Biotech sector can move on news Pure speculative momentum setup. High risk, high reward. Watching for a breakout above trendline resistance.
0 · Reply
Latest News on ESLA
Estrella Immunopharma activates fourth clinical site for STARLIGHT-1 trial

2026-08-11T12:06:37.000Z - 4 weeks ago

Estrella Immunopharma activates fourth clinical site for STARLIGHT-1 trial

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma activates third trial site for Starlight-1 trial

2026-08-03T12:05:50.000Z - 5 weeks ago

Estrella Immunopharma activates third trial site for Starlight-1 trial

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Aug 3, 2026, 8:00 AM EDT - 5 weeks ago

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma activates second clinical site for STARLIGHT-1 trial

2026-07-29T12:10:49.000Z - 6 weeks ago

Estrella Immunopharma activates second clinical site for STARLIGHT-1 trial

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella announces first patient dosed in STARLIGHT-1 Phase I/II trial

2026-07-24T12:05:16.000Z - 7 weeks ago

Estrella announces first patient dosed in STARLIGHT-1 Phase I/II trial

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma

Jul 24, 2026, 8:00 AM EDT - 7 weeks ago

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

May 5, 2026, 8:00 AM EDT - 4 months ago

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Estrella Immunopharma presents updated data on EB103

2026-02-09T12:21:27.000Z - 7 months ago

Estrella Immunopharma presents updated data on EB103

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 9, 2026, 7:00 AM EST - 7 months ago

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 3, 2026, 8:00 AM EST - 7 months ago

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Jan 6, 2026, 2:02 PM EST - 8 months ago

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Jan 5, 2026, 8:30 AM EST - 8 months ago

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma files to sell 2.54M shares of common stock for holders

2025-12-22T16:00:22.000Z - 8 months ago

Estrella Immunopharma files to sell 2.54M shares of common stock for holders

Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review

2025-12-04T13:15:12.000Z - 9 months ago

Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 9 months ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

2025-11-03T13:10:26.000Z - 10 months ago

Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 10 months ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma regains compliance with Nasdaq

2025-10-06T12:11:06.000Z - 11 months ago

Estrella Immunopharma regains compliance with Nasdaq

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma announces additional site for STARLIGHT-1 trial

2025-06-05T12:31:13.000Z - 1 year ago

Estrella Immunopharma announces additional site for STARLIGHT-1 trial

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement

2025-06-03T12:20:42.000Z - 1 year ago

Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial

2025-05-29T12:10:26.000Z - 1 year ago

Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 1 year ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma completes first dose cohort in STARLIGHT trial

2025-02-21T13:55:36.000Z - 1 year ago

Estrella Immunopharma completes first dose cohort in STARLIGHT trial

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 1 year ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma initiated with a Buy at D. Boral Capital

2025-02-18T12:16:45.000Z - 1 year ago

Estrella Immunopharma initiated with a Buy at D. Boral Capital

Estrella Immunopharma files $100M common stock, warrants offering

2024-12-12T22:15:11.000Z - 1 year ago

Estrella Immunopharma files $100M common stock, warrants offering

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma names Hong Zhang as chairperson

2024-08-14T16:01:35.000Z - 2 years ago

Estrella Immunopharma names Hong Zhang as chairperson

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 2 years ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Stay_Greens
Stay_Greens Sep. 7 at 11:48 PM
$ONMD $ESLA $PAAI $ONMD $SLXN $BYRN this week
1 · Reply
stinstewart
stinstewart Sep. 4 at 6:36 PM
$ESLA a lot of insider activity in August. Go to their website under investors and look at filings. FYI and For whatever that is worth. Low cash isn't good but this company has high insider stock ownership and i thought the last raise was at market price when stock was trading in the 1.40 area.
0 · Reply
ZacksSCR
ZacksSCR Aug. 26 at 4:44 PM
$ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial https://buff.ly/jII5QIv
0 · Reply
rolandpuski
rolandpuski Jul. 17 at 3:43 PM
$ESLA volume spike... 0,94
0 · Reply
BonjerminFranklin
BonjerminFranklin Jul. 16 at 6:33 PM
$ESLA wtf happen here!! Lowest of lows. Goes to .50 cents will take a casino spin for the double up.
0 · Reply
ZacksSCR
ZacksSCR Jul. 14 at 2:23 PM
$ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma? https://buff.ly/23P2R3Z
0 · Reply
focafoca99
focafoca99 Jun. 30 at 9:48 PM
$ESLA ratified the appointment of Macias Gini & O'Connell LLP as its independent accounting firm at the annual meeting.
0 · Reply
topstockalerts
topstockalerts Jun. 23 at 1:15 PM
Pre Market Top Gainers PT2 $MGN $GITS $VTAK $BLZE $ESLA
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 11 at 1:55 AM
$ESLA
0 · Reply
MTRADe_01
MTRADe_01 Jun. 5 at 2:04 PM
$ESLA Not a squeeze play. But… ✅ Float: ~14.1M ✅ Trading near 52-week lows ✅ Volume running above average ✅ Biotech sector can move on news Pure speculative momentum setup. High risk, high reward. Watching for a breakout above trendline resistance.
0 · Reply
MTRADe_01
MTRADe_01 Jun. 5 at 1:28 PM
$ESLA on watch this morning 👀 • $49M market cap • 17.25M float • 59.9% insider ownership • Trading near 52-week lows • Potential value/speculation setup if volume returns Not a trade yet for me, but keeping it on the radar for a break of the downtrend and a volume surge.
0 · Reply
ThatEscalatedQuickly
ThatEscalatedQuickly May. 25 at 8:21 PM
$SBFM holding $GOVX $FEMY Looking to take a position on $MNTS before the road show 6/4 Watching for technical set up. 3 previous r/s. Micro float, space x ipo sympathy play Watching $ESLA DWTX Blackrock receht 13G
0 · Reply
ThatEscalatedQuickly
ThatEscalatedQuickly May. 25 at 3:09 PM
$SBFM $FEMY $GOVX $ESLA $DWTX Have you ever dreampt a play squeezes and then you wake ⏰️ up & check your device 🙄 I just dreampt $SBFM was at 1, my heart was racing 👀📈 in a good way 👍🏼 Check back later 😎💰🔥 Let's go Bullz!
1 · Reply
ThatEscalatedQuickly
ThatEscalatedQuickly May. 25 at 12:14 PM
$SBFM $GOVX $FEMY $ESLA $DWTX $SBFM ▶️ moving away from news, pipeline, 13G filings, offerings, etc. Here is the technical set up i like 👍🏼 Post offering sell off, we have a reversal with a bull pennant, followed by a bull flag later in the week. Friday was 8 consecutive days closing under $1. I think $SBFM is safe for the next 10 training days Good luck Bulls 👍🏼
0 · Reply
ThatEscalatedQuickly
ThatEscalatedQuickly May. 25 at 1:40 AM
$SBFM $GOVX $FEMY Holding Watching 👀 $ESLA $DWTX now with recent 13G filings
0 · Reply
stinstewart
stinstewart May. 22 at 3:16 PM
$ESLA not nasdex compliant per my fidelity account
0 · Reply
BecauseOfScout
BecauseOfScout Apr. 8 at 3:54 PM
$ESLA Registered warrants at $1.39 making it hard for this to move up further. Heavy supply of located available — when’s the PR? Asking for a friend…
0 · Reply
Arcides
Arcides Apr. 7 at 9:45 PM
$BMEA $ESLA $PRLD on fire
0 · Reply
Soyaz
Soyaz Apr. 7 at 3:06 PM
$ESLA
0 · Reply
neangewo
neangewo Apr. 6 at 5:21 PM
$ESLA Up on big volume and no news! Took a starter for a swing!
0 · Reply
ZacksSCR
ZacksSCR Mar. 26 at 8:39 PM
CAR-T therapy has reshaped oncology, but toxicity and durability remain challenges. $ESLA's ARTEMIS® platform is built to address both. Zacks SCR initiates coverage with early STARLIGHT-1 data showing a 100% CR rate at dose level 2. #CARTCell #Biotech #Oncology #SmallCap https://youtu.be/JoD4rNMoY-s
1 · Reply
ZacksSCR
ZacksSCR Mar. 18 at 1:23 PM
$ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T https://buff.ly/hJfckaA
0 · Reply